Danielle M. Brander

CME Opportunity: Join #DukeDebates2024, presented by #DukeCancerNetwork in collaboration with @DukeCancer. April 12-14, 2024, Hilton Head, SC Register here: bit.ly/DukeDebates CME credit available. Earn up to 12 MOC Part 2 points. #DukeCancerInstitute #MedEd

@MrazLab Amazing - congratulations!! So honored to have known you these years and witness all you’ve accomplished.

I am very honored to be named a Full Professor at Masaryk University. Big thanks to all the colleagues and collaborators that I was lucky to work with during the years, and my family for so much support.

Ask your doctor if you are considered high risk by the CLLIPI score. If so, you may qualify for this exciting study. #CLL @SWOG @BrianHill_MDPhD @mshadman @anthonymatomd @dbranderMD @DanilovLab

Outstanding commentary by ⁦@DebbieMStephens⁩ from ⁦@huntsmancancer⁩ on the recent publication on the ELEVATE-RR study comparing ibrutinib and acalabrutinib in R/R CLL in ⁦@JCO_ASCO⁩ ascopubs.org/doi/abs/10.120…

Just out - our multicenter effort to dissect comorbidities in CLL ⁦@mshadman⁩ ⁦@DrDanPersky⁩ ⁦@dbranderMD⁩ ⁦@matthew_mei⁩ ⁦@jonathonbcohen⁩ ⁦@KrishPatelMD⁩ ⁦@BrianHill_MDPhD⁩ ⁦@DebbieMStephens⁩ clincancerres.aacrjournals.org/content/early/…

Thanks to the @CllSociety for all you do for our patients. Happy New Year!

Important MURANO tox ax @anthonymatomd @jeff_sharman et al 28% premature d/c VR<2y ⬇️ PFS in prem d/c ven for any reason (PD excluded;p<0.0001)+due to AE Interrupt for AE 69% / dose ⬇️ 23% both no impact on PFS/OS Tox mx+continued Rx important for VenR PFS outcome #CLL #lymsm

#ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer Phase I trial incorporating NK cells for patients w/ #CML & MRD after TKI therapy. #leusm bit.ly/3osWQ7x

There may not have been an official ASH run this year, but anyone else still get in their #FauciFour ? If daily running is the secret to Dr Fauci leading the nation through this chaos, may I never stop. Also, the San Diego skyline has nothing on my view. #IRunForASH

@DukeHMCT @DukeFellows @DukeCancer

Flashback Friday and my upcoming first Twitter-versary. This tweet from an amazing #cll leader, along with a little help from @chadinabhan and @anthonymatomd finally got me on board. Looking forward to #ash20 highlights and my first ash on Twitter.

@cmpabon Well said! Also sad that even when insurance “covers” - most patients are very much underinsured and co pays are limiting.

Frontline therapy in #CLL has largely evolved with novel therapies in the last decade. Sad to hear that despite the data, sometimes we still choose chemoimmunotherapy if insurance doesn't cover targeted agents. Our healthcare system needs a makeover! #ASH2020 @ASH_hematology

To teach is to learn, twice And thankful for this opportunity from #ASH20, twice - to learn from so many others but also to work on this with an amazing fellow @DukeFellows, Dr Ashley Hanlon @amilliga, that has taught me so much and co authored this chapter #dukefamily

@tomleblancMD @DukeCancer @DukeHMCT Thanks for the support!

Kudos to Dr. Danielle Brander @dbranderMD from @DukeCancer who is presenting a prestigious #ASH20 Education Program Session on management of toxicities w/targeted therapies in #CLL, this Sunday at 2pm pacific. Don't miss it! @DukeHMCT #leusm #19106" target="_blank" rel="nofollow noopener">hematology.org/meetings/annua…

We are so excited to welcome @_joycehwang @andrewpeseski @FahminB_MDPhD Drs. Kathrine DiNardo, Cameron Oswalt, Grayce Selig, and Cameron Wood to the Duke Heme/Onc Fellowship Program! We are so excited to have you join our wards and clinics in July 2021! @DukeCancer @dukemedicine

Intolerance is a failure of the medication for that given patient, patients don’t fail therapy. Grateful to be a part of this collaborative effort @DukeHMCT and for all trials aimed at the unmet need of intolerance. @anthonymatomd @AndreaSitlinger and many others